Global Exporter & Bulk Supplier: Imalieva 400mg Tablet
🌍 Market Overview
Are you trying to find a reliable, verified international supply chain partner for high-demand targeted oral oncology treatments? Ernest Oncology (the specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd.) operates as a leading international exporter, bulk supplier, and distributor of Imalieva 400mg Tablets.
Utilizing our established, secure pharmaceutical distribution infrastructure, we handle efficient, high-capacity export logistics to supply Imatinib 400mg directly to global hospital networks, specialized oncological clinics, international pharmacy groups, and government health tenders across the USA, UK, Australia, and South Africa.
🔬 Product Profile: Imalieva 400mg Tablet
Imalieva 400mg contains Imatinib Mesylate, a breakthrough oral antineoplastic agent belonging to the small-molecule Tyrosine Kinase Inhibitor (TKI) therapeutic class.
Active Ingredient: Imatinib Mesylate (400mg)
Therapeutic Class: Antineoplastic / Small-Molecule Tyrosine Kinase Inhibitor (TKI)
Mechanism of Action: It selectively inhibits the BCR-ABL tyrosine kinase (the abnormal fusion protein created by the Philadelphia chromosome abnormality), as well as receptor tyrosine kinases for KIT (CD117) and Platelet-Derived Growth Factor Receptors (PDGFR).
By blocking these enzymes, Imalieva 400mg stops cellular proliferation and induces apoptosis (programmed cell death) in positive malignant cell lines without harming healthy tissue. Primary Indications: * Chronic Myeloid Leukemia (CML): Indicated for the first-line systemic treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) CML in the chronic phase, accelerated phase, or blast crisis.
Acute Lymphoblastic Leukemia (Ph+ ALL): Used in combination regimens for adults and children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Gastrointestinal Stromal Tumors (GIST): Prescribed for the treatment of adult patients with KIT (CD117)-positive unresectable, malignant, and/or metastatic gastrointestinal stromal tumors, and as adjuvant therapy post-resection.
Other Rare Malignancies: Utilized in the clinical management of Myelodysplastic/Myeloproliferative Diseases (MDS/MPD), Hypereosinophilic Syndrome (HES), Chronic Eosinophilic Leukemia (CEL), and Dermatofibrosarcoma Protuberans (DFSP).
Administration Protocol: To minimize the risk of gastrointestinal irritation and nausea, the tablet must be swallowed whole with a large glass of water during a substantial meal.
📦 Logistics & Sourcing Capabilities
Compliant Supply Lines: Procured through fully validated, legal pharmaceutical distribution pathways operating under global Good Manufacturing Practices (GMP) and compliance benchmarks.
Streamlined International Export: Specialized global logistics protocols engineered to handle strict customs clearance, temperature-controlled shipping lanes, and individual regulatory import paperwork within the USA, UK, Australia, and South Africa.
Institutional Sourcing Power: Fully scalable commercial operations ready to fulfill wholesale contracts for ministries of health, cancer research networks, and large commercial distributors.
B2B Documentation Suite: Every batch is exported with a comprehensive portfolio, including verified Certificates of Analysis (COA), export invoice clearances, and tracking documentation.
PRESCRIPTION MEDICINE IS: YES
⚠️Disclaimer
Imalieva 400mg Tablet is a potent, targeted prescription antineoplastic medication.
📞 Contact Ernest Oncology — Global Medicine Exporter
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
🌐 Websites:
📧 Email: exports@ernestpharmaceuticals.com
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 WhatsApp Direct Link:https://wa.me/919359902383
